Comparison of effectiveness of sitagliptin and nateglinide in type 2 diabetes.

Comparison of effectiveness of sitagliptin and nateglinide in type 2 diabetes. - SiTagliptin AND nAteglinide RandomizeD clinical study (STANDARD Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006278

Enrollment

Registered

2011-09-02

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Sitagliptin treatment, 3 months Glinides treatment, 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients whose HbA1c level is more than 6.5% even after diet, excise. 1. The patients whose HbA1c are between 6.1 % and 8.0%. 2. The patients whose fasting glucose is less than 140 mg/dL. 3. The patients who have already started diet and exercise therapy for more than 3 months. 4. Patients who are more than 20 year-old. 5. No restriction on sex 6. The patients who are able to read and understand the written informed consent.

Exclusion criteria

Exclusion criteria: 1.Contraindication for sitagliptin. 2.Contraindication for nateglinide. 3.Pregnant or possible pregnant. 4.Patients with sever liver failure or renal failure. 5.Patients considered not eligible for the study by the attending doctor due to other reasons.

Design outcomes

Primary

Measure	Time frame
HbA1c, Apo-B48, TG, glucose	—

Secondary

Measure	Time frame
GA, 1,5-AG, insulin, glucagon, adiponectin, Apo-A1, Apo-C3, Apo-B	—

Countries

Japan

Contacts

Public ContactYuichi Kojima

Japanese Red Cross Medical Center Division of Diabetes and Endcrinolgy

03-3400-1311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026